ANI PharmaceuticalsANIP +1.52%77 PB Ratio is 3.44 as of Jun. 28, 2026, which is 11% above its 10-year median of 3.10. GuruFocus rates ANIP with a GF Score™ of 77/100 and a GF Value™ of $98.62 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 923 Drug Manufacturers companies, ANI Pharmaceuticals ranks worse than 73.13% on this metric.
The historical rank and industry rank for ANI Pharmaceuticals's PB Ratio or its related term are showing as below:
ANIP'
s PB Ratio Range Over the Past 10 Years
Min: 1.31 Med: 3.1 Max: 4.95
Current: 3.44
During the past 13 years, ANI Pharmaceuticals's highest PB Ratio was 4.95. The lowest was 1.31. And the median was 3.10.
ANIP's PB Ratio is ranked worse than 73.13% of 923
companies
in the Drug Manufacturers industry
Industry Median: 1.81
vs ANIP: 3.44
During the past 12 months, ANI Pharmaceuticals's average Book Value Per Share Growth Rate was 27.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 4.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ANI Pharmaceuticals was 50.90% per year. The lowest was -40.10% per year. And the median was 6.10% per year.
Back to Basics: PB Ratio
ANI Pharmaceuticals (NAS:ANIP) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ANI Pharmaceuticals PB Ratio Related Terms
ANI Pharmaceuticals PB Ratio Historical Data
* Premium members only.
The historical data trend for ANI Pharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ANI Pharmaceuticals (ANIP) has a PB Ratio of 3.44 as of Jun. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ANI Pharmaceuticals and its competitors. This is 11% above median its historical median of 3.10. Over the past decade, ANI Pharmaceuticals' PB Ratio has ranged from 1.31 to 4.95. According to the industry distribution chart, ANI Pharmaceuticals ranks #675 out of 923 companies in the Drug Manufacturers industry, placing it in the top 73.1%.
Is ANI Pharmaceuticals' PB Ratio too high?
ANI Pharmaceuticals' current PB Ratio of 3.44 is 11% above median its 10-year median of 3.10. Over the past 10 years, this metric has ranged from a low of 1.31 to a high of 4.95. The Drug Manufacturers industry median PB Ratio is 1.81. ANI Pharmaceuticals' value of 3.44 is 90.1% above this industry median. Based on the distribution chart, ANI Pharmaceuticals ranks #675 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ANI Pharmaceuticals has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' PB Ratio compare to AMLX and PRGO?
According to the Drug Manufacturers industry distribution chart, ANI Pharmaceuticals ranks #675 out of 923 companies for PB Ratio. This places ANI Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 1.81. ANI Pharmaceuticals' value of 3.44 is 90.1% above this benchmark. Historically, ANI Pharmaceuticals' own PB Ratio has ranged from 1.31 to 4.95 over the past decade. While the company's 10-year median is 3.10 vs. the industry median of 1.81, ANI Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.81, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANI Pharmaceuticals's current PB Ratio of 3.44 is 90.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ANI Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANI Pharmaceuticals's current PB Ratio is 3.44, which is 11% above median its own 10-year median of 3.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (ANIP) is currently considered Modestly Undervalued. The stock's GF Value™ is $98.62, compared to a current price of $84.49 — trading 14.3% below its estimated fair value. The current PB Ratio is 3.44, which is 11% above median its 10-year median of 3.10 and 90.1% above the Drug Manufacturers industry median of 1.81. ANI Pharmaceuticals' overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ANI Pharmaceuticals (ANIP), the current PB Ratio is 3.44 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANI Pharmaceuticals (ANIP) Overvalued in 2026?
Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued.
The current stock price of $84.49 is trading 14.3% below its estimated GF Value™ of $98.62.
GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for ANIP:
PB Ratio: 3.44 (11% above median its 10-year median of 3.10)
GF Value™: $98.62 vs. price of $84.49 (14.3% below fair value)
Industry Position: 90.1% above the Drug Manufacturers median (#675 of 923)
No single metric tells the full story. See the ANIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
77GF Score
Get the complete analysis for ANIP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIP has been successfully added to your 
